Barclays PLC Exagen Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Exagen Inc. stock. As of the latest transaction made, Barclays PLC holds 5,145 shares of XGN stock, worth $10,032. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,145
Previous 5,145
-0.0%
Holding current value
$10,032
Previous $10,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding XGN
# of Institutions
35Shares Held
6.21MCall Options Held
1.6KPut Options Held
4.1K-
Rtw Investments, LP New York, NY1.5MShares$2.93 Million0.04% of portfolio
-
Cowen And Company, LLC899KShares$1.75 Million0.05% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT787KShares$1.53 Million0.01% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY545KShares$1.06 Million0.01% of portfolio
-
Perkins Capital Management Inc494KShares$962,4630.68% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $31.7M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...